LLamdaGen Corporation is the leader in plasmonic-based diagnostic/detection technologies that are rapid, highly sensitive, easy to use and accessible. We are taking a One Health approach to advancing testing solutions for Human Health, Animal Health and Food & Water Safety with the patented LAuRA™ Digital Detection platform, powered by PAT™. LAuRA enables rapid diagnostics with the high sensitivity and quantitation of multi-step lab-based ELISAs with the simplicity and ease of use of lateral flow tests. The proprietary basis of LAuRA is LamdaGen’s game-changing Plasmonic Amplification Technology (PAT). PAT is a ‘double amplification system’ that leverages the inherent properties of nano-based plasmonics enabling limits of detection up to 100 times better than those of current lateral flow products. The LAuRA platform is a simple, compact, cost-effective and CLIA-waivable, providing central laboratory precision and high-sensitivity detection in a 15 minute, no wash step testing protocol. This powerful platform is amenable to a range of detection products - from lab based throughput solutions, to small benchtops and miniaturized handhelds, to smartphone based systems. LamdaGen is a technology holding company with a serial spin-off business model aimed at optimizing value by leveraging the platform beyond human clinical testing and into the Food Safety, Animal Health and Biopharmaceutical Development sectors with stand-alone solutions tailored for those markets. We invite you to explore partnering opportunities with us.